New England Journal of Medicine· 2022Q1

Teclistamab in Relapsed or Refractory Multiple Myeloma

Philippe Moreau, Alfred L. Garfall, Niels W.C.J. van de Donk, Hareth Nahi et al.

1,135citations
Q1SCImago
2022year

Short summary

Teclistamab, a bispecific antibody targeting CD3 and BCMA, achieved a 63.0% overall response rate in patients with relapsed/refractory multiple myeloma after a median of 5 prior therapies.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Hematology

HematologyMedicine